Eyal C. Attar
2022
In 2022, Eyal C. Attar earned a total compensation of $775.4K as Chief Medical Officer at Aprea Therapeutics, a 59% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $115,529 |
|---|---|
| Option Awards | $252,824 |
| Salary | $328,956 |
| Stock Awards | $78,078 |
| Total | $775,387 |
Attar received $329K in salary, accounting for 42% of the total pay in 2022.
Attar also received $115.5K in non-equity incentive plan, $252.8K in option awards and $78.1K in stock awards.
Rankings
In 2022, Eyal C. Attar's compensation ranked 3,571st out of 5,756 executives tracked by ExecPay. In other words, Attar earned more than 38.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,571 out of 5,756 | 38th |
Division Manufacturing | 2,030 out of 3,133 | 35th |
Major group Chemicals And Allied Products | 972 out of 1,419 | 32nd |
Industry group Drugs | 909 out of 1,320 | 31st |
Industry Pharmaceutical Preparations | 662 out of 966 | 32nd |
Source: SEC filing on July 11, 2023.
Attar's colleagues
We found four more compensation records of executives who worked with Eyal C. Attar at Aprea Therapeutics in 2022.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020